Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis

Abstract

Zhang Hongjiao, Jiang Jie, Huang Wei. Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis[J]. Journal of International Oncology, 2022, 49(1): 51-55.

References44

[1]	Karki K, Saraiya S, Hugo GD, et al. Variabilities of magnetic resonance imaging-, computed tomography-, and positron emission tomography-computed tomography-based tumor and lymph node delineations for lung cancer radiation therapy planning[J]. Int J Radiat Oncol Biol Phys, 2017, 99(1):80-89. DOI: 10.1016/j.ijrobp.2017.05.002. doi:10.1016/j.ijrobp.2017.05.002
[2]	Prathipati A, Manthri RG, Subramanian BV, et al. A prospective study comparing functional imaging (¹⁸F-FDG PET) versus anatomical imaging (contrast enhanced CT) in dosimetric planning for non-small cell lung cancer[J]. Asia Ocean J Nucl Med Biol, 2017, 5(2):75-84. DOI: 10.22038/aojnmb.2017.8706. doi:10.22038/aojnmb.2017.8706pmid:28660217
[3]	Sibille L, Seifert R, Avramovic N, et al.¹⁸F-FDG PET/CT uptake classification in lymphoma and lung cancer by using deep convolutional neural networks[J]. Radiology, 2020, 294(2):445-452. DOI: 10.1148/radiol.2019191114. doi:10.1148/radiol.2019191114
[4]	Konert T, Vogel WV, Paez D, et al. Introducing FDG PET/CT-guided chemoradiotherapy for stage Ⅲ NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial[J]. Eur J Nucl Med Mol Imaging, 2019, 46(11):2235-2243. DOI: 10.1007/s00259-019-04421-5. doi:10.1007/s00259-019-04421-5
[5]	Schaefer A, Kim YJ, Kremp S, et al. PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings[J]. Eur J Nucl Med Mol Imaging, 2013, 40(8):1233-44. DOI: 10.1007/s00259-013-2407-x. doi:10.1007/s00259-013-2407-x
[6]	Kajáry K, Lengyel Z, Tokés AM, et al. Dynamic FDG-PET/CT in the initial staging of primary breast cancer: clinicopathological correlations[J]. Pathol Oncol Res, 2020, 26(2):997-1006. DOI: 10.1007/s12253-019-00641-0. doi:10.1007/s12253-019-00641-0
[7]	Bianconi F, Palumbo I, Fravolini ML, et al. Texture analysis on [¹⁸F]FDG PET/CT in non-small-cell lung cancer: correlations between PET features, CT features, and histological types[J]. Mol Imaging Biol, 2019, 21(6):1200-1209. DOI: 10.1007/s11307-019-01336-3. doi:10.1007/s11307-019-01336-3
[8]	Yin LJ, Yu XB, Ren YG, et al. Utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis[J]. Multidiscip Respir Med, 2013, 8(1):21. DOI: 10.1186/2049-6958-8-21. doi:10.1186/2049-6958-8-21
[9]	Fonti R, Conson M, Del Vecchio S. PET/CT in radiation oncology[J]. Semin Oncol, 2019, 46(3):202-209. DOI: 10.1053/j.seminoncol.2019.07.001. doi:S0093-7754(19)30079-Xpmid:31378377
[10]	Flechsig P, Rastgoo R, Kratochwil C, et al. Impact of computer-aided CT and PET analysis on non-invasive T staging in patients with lung cancer and atelectasis[J]. Mol Imaging Biol, 2018, 20(6):1044-1052. DOI: 10.1007/s11307-018-1196-9. doi:10.1007/s11307-018-1196-9pmid:29679299
[11]	Fiset S, Welch ML, Weiss J, et al. Repeatability and reproducibility of MRI-based radiomic features in cervical cancer[J]. Radiother Oncol, 2019, 135:107-114. DOI: 10.1016/j.radonc.2019.03.001. doi:10.1016/j.radonc.2019.03.001
[12]	Pavic M, Bogowicz M, Würms X, et al. Influence of inter-observer delineation variability on radiomics stability in different tumor sites[J]. Acta Oncol, 2018, 57(8):1070-1074. DOI: 10.1080/0284186X.2018.1445283. doi:10.1080/0284186X.2018.1445283
[13]	刘陈路, 马长升, 陈进琥, 等. PET-CT SUV阈值对非小细胞肺癌靶区勾画体积及对影像组学指标的影响[J]. 中华肿瘤防治杂志, 2020, 27(22):1815-1820. DOI: 10.16073/j.cnki.cjcpt.2020.22.07. doi:10.16073/j.cnki.cjcpt.2020.22.07
[14]	Yousaf T, Dervenoulas G, Politis M. Advances in MRI methodology[J]. Int Rev Neurobiol, 2018, 141:31-76. DOI: 10.1016/bs.irn.2018.08.008. doi:10.1016/bs.irn.2018.08.008
[15]	Khalil A, Majlath M, Gounant V, et al. Contribution of magnetic resonance imaging in lung cancer imaging[J]. Diagn Interv Imaging, 2016, 97(10):991-1002. DOI: 10.1016/j.diii.2016.08.015. doi:10.1016/j.diii.2016.08.015
[16]	Zhang X, Fu Z, Gong G, et al. Implementation of diffusion-weighted magnetic resonance imaging in target delineation of central lung cancer accompanied with atelectasis in precision radiotherapy[J]. Oncol Lett, 2017, 14(3):2677-2682. DOI: 10.3892/ol.2017.6479. doi:10.3892/ol.2017.6479
[17]	谢青, 任彤, 孙梅, 等. DWI-MRI对区分中央型肺癌与阻塞性肺不张的价值[J]. 中国临床研究, 2020, 33(8):1097-1100. DOI: 10.13429/j.cnki.cjcr.2020.08.023. doi:10.13429/j.cnki.cjcr.2020.08.023
[18]	Eun NL, Kang D, Son EJ, et al. Texture analysis with 3.0-T MRI for association of response to neoadjuvant chemotherapy in breast cancer[J]. Radiology, 2020, 294(1):31-41. DOI: 10.1148/radiol.2019182718. doi:10.1148/radiol.2019182718
[19]	Sarioglu FC, Sarioglu O, Guleryuz H, et al. MRI-based texture analysis for differentiating pediatric craniofacial rhabdomyosarcoma from infantile hemangioma[J]. Eur Radiol, 2020, 30(10):5227-5236. DOI: 10.1007/s00330-020-06908-4. doi:10.1007/s00330-020-06908-4pmid:32382846
[20]	Sarioglu O, Sarioglu FC, Akdogan AI, et al. MRI-based texture analysis to differentiate the most common parotid tumours[J]. Clin Radiol, 2020, 75(11): 877.e15-877.e23. DOI: 10.1016/j.crad.2020.06.018. doi:10.1016/j.crad.2020.06.018
[21]	Mao J, Fang J, Duan X, et al. Predictive value of pretreatment MRI texture analysis in patients with primary nasopharyngeal carcinoma[J]. Eur Radiol, 2019, 29(8):4105-4113. DOI: 10.1007/s00330-018-5961-6. doi:10.1007/s00330-018-5961-6
[22]	Ortiz-Ramón R, Ruiz-Espana S, Mollá-Olmos E, et al. Glioblastomas and brain metastases differentiation following an MRI texture analysis-based radiomics approach[J]. Phys Med, 2020, 76:44-54. DOI: 10.1016/j.ejmp.2020.06.016. doi:S1120-1797(20)30149-6pmid:32593138
[23]	Xu J, Cui X, Wang B, et al. Texture analysis of early cerebral tissue damage in magnetic resonance imaging of patients with lung cancer[J]. Oncol Lett, 2020, 19(4):3089-3100. DOI: 10.3892/ol.2020.11426. doi:10.3892/ol.2020.11426
[24]	Mahon RN, Hugo GD, Weiss E. Repeatability of texture features derived from magnetic resonance and computed tomography imaging and use in predictive models for non-small cell lung cancer outcome[J]. Phys Med Biol, 2019, 64(14):145007. DOI: 10.1088/1361-6560/ab18d3. doi:10.1088/1361-6560/ab18d3
[25]	Wang C, Tyagi N, Rimner A, et al. Segmenting lung tumors on longitudinal imaging studies via a patient-specific adaptive convolutional neural network[J]. Radiother Oncol, 2019, 131:101-107. DOI: 10.1016/j.radonc.2018.10.037. doi:10.1016/j.radonc.2018.10.037
[26]	Hearn N, Bugg W, Chan A, et al. Manual and semi-automated delineation of locally advanced rectal cancer subvolumes with diffusion-weighted MRI[J]. Br J Radiol, 2020, 93(1114):20200543. DOI: 10.1259/bjr.20200543. doi:10.1259/bjr.20200543
[27]	邹茂扬, 杨昊, 潘光晖, 等. 深度学习在医学图像配准上的研究进展与挑战[J]. 生物医学工程学杂志, 2019, 36(4):677-683. DOI: 10.7507/1001-5515.201810004. doi:10.7507/1001-5515.201810004
[28]	Hu R, Wang H, Ristaniemi T, et al. Lung CT image registration through landmark-constrained learning with convolutional neural network[J]. Annu Int Conf IEEE Eng Med Biol Soc, 2020, 2020:1368-1371. DOI: 10.1109/EMBC44109.2020.9176363. doi:10.1109/EMBC44109.2020.9176363
[29]	Han Q, Liang H, Cheng P, et al. Comparison of different registration landmarks for MRI-CT fusion in radiotherapy for lung cancer with post-obstructive lobar collapse[J]. J Appl Clin Med Phys, 2019, 20(1):50-54. DOI: 10.1002/acm2.12495. doi:10.1002/acm2.12495
[30]	Higgins J, Bezjak A, Franks K, et al. Comparison of spine, carina, and tumor as registration landmarks for volumetric image-guided lung radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2009, 73(5):1404-1413. DOI: 10.1016/j.ijrobp.2008.06.1926. doi:10.1016/j.ijrobp.2008.06.1926
[31]	de Vos BD, Berendsen FF, Viergever MA, et al. A deep learning framework for unsupervised affine and deformable image registration[J]. Med Image Anal, 2019, 52:128-143. DOI: 10.1016/j.media.2018.11.010. doi:10.1016/j.media.2018.11.010
[32]	Aldosary G, Szanto J, Holmes O, et al. Geometric inaccuracy and co-registration errors for CT, DynaCT and MRI images used in robotic stereotactic radiosurgery treatment planning[J]. Phys Med, 2020, 69:212-222. DOI: 10.1016/j.ejmp.2019.12.002. doi:S1120-1797(19)30523-Xpmid:31918373
[33]	刘士远, 肖湘生, 李成州, 等. MRI区分肺癌肿块与阻塞性肺炎或肺不张: 与CT对照[J]. 中国医学计算机成像杂志, 1997, (3):172-174. DOI: 10.19627/j.cnki.cn31-1700/th.1997.03.008. doi:10.19627/j.cnki.cn31-1700/th.1997.03.008
[34]	Li L, Lu W, Tan S. Variational PET/CT tumor co-segmentation integrated with PET restoration[J]. IEEE Trans Radiat Plasma Med Sci, 2020, 4(1):37-49. DOI: 10.1109/trpms.2019.2911597. doi:10.1109/trpms.2019.2911597
[35]	Sindoni A, Minutoli F, Pontoriero A, et al. Usefulness of four dimensional (4D) PET/CT imaging in the evaluation of thoracic lesions and in radiotherapy planning: review of the literature[J]. Lung Cancer, 2016, 96:78-86. DOI: 10.1016/j.lungcan.2016.03.019. doi:10.1016/j.lungcan.2016.03.019
[36]	Reinartz G, Haverkamp U, Wullenkord R, et al. 4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma: determination of intra- and interfractional gastric motion[J]. Strahlenther Onkol, 2016, 192(5):322-332. DOI: 10.1007/s00066-016-0949-0. doi:10.1007/s00066-016-0949-0
[37]	Scarsbrook A, Ward G, Murray P, et al. Respiratory-gated (4D) contrast-enhanced FDG PET-CT for radiotherapy planning of lower oesophageal carcinoma: feasibility and impact on planning target volume[J]. BMC Cancer, 2017, 17(1):671. DOI: 10.1186/s12885-017-3659-9. doi:10.1186/s12885-017-3659-9pmid:28978306
[38]	Hapdey S, Dubray B, Chastan M, et al. Respiratory gated multistatic PET reconstructions to delineate radiotherapy target volume in patients with mobile lung tumours[J]. Q J Nucl Med Mol Imaging, 2020. DOI: 10.23736/S1824-4785.19.03183-2. doi:10.23736/S1824-4785.19.03183-2
[39]	Navest RJM, Mandija S, Bruijnen T, et al. The noise navigator: a surrogate for respiratory-correlated 4D-MRI for motion characterization in radiotherapy[J]. Phys Med Biol, 2020, 65(1): 01NT02. DOI: 10.1088/1361-6560/ab5c62. doi:10.1088/1361-6560/ab5c62
[40]	Wang FL, Tan YY, Gu XM, et al. Comparison of positron emission tomography using 2-[¹⁸F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[¹⁸F]-fluorothymidine in lung cancer imaging[J]. Chin Med J (Engl), 2016, 129(24):2926-2935. DOI: 10.4103/0366-6999.195468. doi:10.4103/0366-6999.195468
[41]	Shimizu K, Kaira K, Higuchi T, et al. Relationship between tumor immune markers and fluorine-18-α-methyltyrosine ([¹⁸F]FAMT) uptake in patients with lung cancer[J]. Mol Imaging Biol, 2020, 22(4):1078-1086. DOI: 10.1007/s11307-019-01456-w. doi:10.1007/s11307-019-01456-w
[42]	Cheng G. Non-small-cell lung cancer PET imaging beyond F18 fluorodeoxyglucose[J]. PET Clin, 2018, 13(1):73-81. DOI: 10.1016/j.cpet.2017.09.006. doi:S1556-8598(17)30103-7pmid:29157387
[43]	Windisch P, Zwahlen DR, Koerber SA, et al. Clinical results of fibroblast activation protein (FAP) specific PET and implications for radiotherapy planning: systematic review[J]. Cancers (Basel), 2020, 12(9):2629. DOI: 10.3390/cancers12092629. doi:10.3390/cancers12092629
[44]	Prosch H. Pulmonary carcinoid tumors[J]. Radiologe, 2017, 57(5):397-406. DOI: 10.1007/s00117-017-0243-x. doi:10.1007/s00117-017-0243-xpmid:28405692

Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References44

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[6]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[7]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[11]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[12]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version）[J]. Journal of International Oncology, 2023, 50(4): 193-201.
[13]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng.Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance[J]. Journal of International Oncology, 2023, 50(4): 227-230.
[14]	Shi Xaioqi, Wang Hongyan.Research progress on the interaction between gut microbiota and radiation enteritis[J]. Journal of International Oncology, 2023, 50(4): 244-247.
[15]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun.Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases[J]. Journal of International Oncology, 2023, 50(3): 138-143.